THE EFFICACY AND SAFETY OF ALIROCUMAB IN PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: ODYSSEY KIDS

A Phase 2 dose-finding study ([NCT02890992][1]) evaluated the efficacy, safety, and dose selection of the PCSK9 inhibitor alirocumab in pediatric patients with heterozygous familial hypercholesterolemia (HeFH). Patients (N=42) aged 8–17 years, with body weight ≥25 kg and with HeFH and LDL-C ≥